Syncom Formulation (India) (BOM:524470) Cyclically Adjusted Revenue per Share: ₹3.92 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524470 Syncom Formulation (India) Ltd BOM:524470
85 GF Score
Price ₹17.55
GF Value ₹20.47
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Syncom Formulation (India) Cyclically Adjusted Revenue per Share?

Syncom Formulation (India) BOM:524470 +1.98% 85 Cyclically Adjusted Revenue per Share is ₹3.92 as of Jun. 2026. GuruFocus rates BOM:524470 with a GF Score™ of 85/100 and a GF Value™ of ₹20.47 (Modestly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Syncom Formulation (India)'s adjusted revenue per share for the three months ended in Jun. 2026 was ₹1.314. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹3.92 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Syncom Formulation (India)'s average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Syncom Formulation (India) was 7.40% per year. The lowest was 4.30% per year. And the median was 6.20% per year.

As of today (2026-08-26), Syncom Formulation (India)'s current stock price is ₹17.55. Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹3.92. Syncom Formulation (India)'s Cyclically Adjusted PS Ratio of today is 4.48.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Syncom Formulation (India) was 7.83. The lowest was 1.10. And the median was 3.67.


Syncom Formulation (India)  (BOM:524470) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Syncom Formulation (India)'s Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.55/3.92
=4.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Syncom Formulation (India) was 7.83. The lowest was 1.10. And the median was 3.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Syncom Formulation (India) Cyclically Adjusted Revenue per Share Related Terms


Syncom Formulation (India) Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syncom Formulation (India) Cyclically Adjusted Revenue per Share Chart

Syncom Formulation (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.91 3.07 3.19 3.49 3.80

Syncom Formulation (India) Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.57 3.66 3.73 3.80 3.92

BOM:524470 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India) Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s Cyclically Adjusted PS Ratio falls into.


BOM:524470
85GF Score
Syncom Formulation (India) Ltd BOM:524470
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syncom Formulation (India) Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Syncom Formulation (India)'s adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.314/167.3573*167.3573
=1.314

Current CPI (Jun. 2026) = 167.3573.

Syncom Formulation (India) Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.692 102.518 1.130
201606 0.516 105.961 0.815
201703 0.623 105.196 0.991
201706 0.608 107.109 0.950
201709 0.582 109.021 0.893
201712 0.683 109.404 1.045
201803 0.502 109.786 0.765
201806 0.422 111.317 0.634
201809 0.576 115.142 0.837
201812 0.625 115.142 0.908
201903 0.758 118.202 1.073
201906 0.690 120.880 0.955
201909 0.658 123.175 0.894
201912 0.598 126.235 0.793
202003 0.430 124.705 0.577
202006 0.394 127.000 0.519
202009 0.856 130.118 1.101
202012 1.092 130.889 1.396
202103 0.641 131.771 0.814
202106 0.665 134.084 0.830
202109 0.565 135.847 0.696
202112 0.690 138.161 0.836
202203 0.504 138.822 0.608
202206 0.547 142.347 0.643
202209 0.580 144.661 0.671
202212 0.831 145.763 0.954
202303 0.482 146.865 0.549
202306 0.637 150.280 0.709
202309 0.784 151.492 0.866
202312 0.837 152.924 0.916
202403 0.749 153.035 0.819
202406 1.258 155.789 1.351
202409 1.474 157.882 1.562
202412 1.373 158.323 1.451
202503 1.599 157.552 1.699
202506 1.261 159.755 1.321
202509 1.320 162.289 1.361
202512 1.401 163.281 1.436
202603 1.452 164.272 1.479
202606 1.314 167.357 1.314

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹3.92 mean?
Syncom Formulation (India) (BOM:524470) has a Cyclically Adjusted Revenue per Share of ₹3.92 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Syncom Formulation (India) and its competitors.
Is Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share too high?
Syncom Formulation (India)'s current Cyclically Adjusted Revenue per Share is ₹3.92. Overall, Syncom Formulation (India) has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share compare to ZTS?
Syncom Formulation (India)'s Cyclically Adjusted Revenue per Share of ₹3.92 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Syncom Formulation (India) and its competitors. Syncom Formulation (India)'s current Cyclically Adjusted Revenue per Share is ₹3.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹20.47, compared to a current price of ₹17.55 — trading 14.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹3.92. Syncom Formulation (India)'s overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Cyclically Adjusted Revenue per Share is ₹3.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?

Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued. The current stock price of ₹17.55 is trading 14.3% below its estimated GF Value™ of ₹20.47. GuruFocus considers Syncom Formulation (India) to be Modestly Undervalued.

Key valuation signals for BOM:524470:

  • Cyclically Adjusted Revenue per Share: ₹3.92
  • GF Value™: ₹20.47 vs. price of ₹17.55 (14.3% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Syncom Formulation (India) Business Description

Other Exchanges SYNCOMF:India
Address 207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
85GF Score

Get the complete analysis for BOM:524470

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹17.55
Price
₹20.47
GF Value